Search by Drug Name or NDC
NDC 00002-7026-99 JAYPIRCA 100 mg/1 Details
JAYPIRCA 100 mg/1
JAYPIRCA is a ORAL TABLET, COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is PIRTOBRUTINIB.
MedlinePlus Drug Summary
Pirtobrutinib is used to treat mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system) in adults that has returned or is unresponsive to other treatments. Pirtobrutinib is also used to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) or small lymphocytic lymphoma (SLL; a type of cancer that begins mostly in the lymph nodes) in adults who have already been treated with at least two other chemotherapy medications. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply.
Related Packages: 00002-7026-99Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Pirtobrutinib
Product Information
| NDC | 00002-7026 |
|---|---|
| Product ID | 0002-7026_7b7804fa-6603-4aac-a91b-e3f66c0bb98a |
| Associated GPIs | |
| GCN Sequence Number | 084357 |
| GCN Sequence Number Description | pirtobrutinib TABLET 100 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 53627 |
| HICL Sequence Number | 048657 |
| HICL Sequence Number Description | PIRTOBRUTINIB |
| Brand/Generic | Brand |
| Proprietary Name | JAYPIRCA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | pirtobrutinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, COATED |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | PIRTOBRUTINIB |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Bruton's Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibito |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA216059 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00002-7026-99 (00002702699)
| NDC Package Code | 0002-7026-99 |
|---|---|
| Billing NDC | 00002702699 |
| Package | 30 TABLET, COATED in 1 BOTTLE (0002-7026-99) |
| Marketing Start Date | 2023-02-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |